H.C. Wainwright raised the firm’s price target on Apellis (APLS) to $48 from $45 and keeps a Buy rating on the shares. The firm upped revenue projections of Syfovre in 2027 and beyond, raising peak sales to $1B, which it views as conservative. H.C. Wainwright is increasingly optimistic about Syfovre’s long-term blockbuster potential.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise
- Apellis Pharmaceuticals: Solid Syfovre Franchise and Rapid Empaveli Uptake Underpin Buy Rating and Long-Term Upside
- Apellis reports Q4 EPS 47c vs (29c) last year
- APLS Earnings this Week: How Will it Perform?
- Short Report: VNET Group short interest at 4-month high